Comparing the effect of low dose and standard dose Cyproheptadine on BMI enhancement in children aged 2-10 and evaluation of its side effects
- Conditions
- thinness.
- Registration Number
- IRCT20240213060992N1
- Lead Sponsor
- Shahre-kord University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 90
Consent of the child's guardian to participate in the study
Being aware and vigilant of the guardian of the child
Age 2 to 9 years and 6 months at the first visit
BMI Z-score is less than -2 standard deviations in the BMI table according to age and sex of the CDC, which is set based on 15day intervals.
Celiac disease, Crohn's disease, sensitivity to cow's protein, hypothyroidism, hyperthyroidism, congenital megacolon, eosinophilic gastroenteritis, cystic fibrosis and any disease that causes malabsorption.
Allergy to antihistamines
Consumption of other appetite stimulants and multivitamins and zinc in the study
Treatment with growth hormone, gonadotropin-releasing hormone analog, aromatase inhibitors, recombinant human-like growth factor and androgen in the study
Entering stage 1 of puberty including the enlargement of testicles in boys, growth of pubic hair in boys, breast enlargement in girls
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method